{
    "id": "03107b41-0bf9-463a-a6e4-956444373e81",
    "indications": {
        "text": "breo ellipta combination fluticasone furoate , corticosteroid , vilanterol , long-acting beta 2 -adrenergic agonist ( laba ) , indicated : \u2022 maintenance treatment patients chronic obstructive pulmonary disease ( chronic obstructive pulmonary disease ) . ( 1.1 ) \u2022 maintenance treatment asthma patients aged 5 years older . ( 1.2 ) limitations : indicated relief acute bronchospasm . ( 1.3 , 5.2 )",
        "doid_entities": [
            {
                "text": "chronic obstructive pulmonary disease (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "asthma (DOID:2841)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2841"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 oral inhalation . ( 2.3 ) \u2022 maintenance treatment chronic obstructive pulmonary disease : 1 actuation breo ellipta 100/25 mcg daily administered oral inhalation . ( 2.1 ) \u2022 maintenance treatment asthma adult patients aged 18 years older : 1 actuation breo ellipta 100/25 mcg breo ellipta 200/25 mcg daily administered oral inhalation . ( 2.2 ) \u2022 maintenance treatment asthma pediatric patients aged 12 17 years : 1 actuation breo ellipta 100/25 mcg daily administered oral inhalation . ( 2.2 ) \u2022 maintenance treatment asthma pediatric patients aged 5 11 years : 1 actuation breo ellipta 50/25 mcg daily administered oral inhalation . ( 2.2 )",
        "doid_entities": [
            {
                "text": "chronic obstructive pulmonary disease (DOID:3083)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3083"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "asthma (DOID:2841)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2841"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "breo ellipta supplied disposable light grey pale blue plastic inhaler containing 2 foil strips , 30 blisters ( 14 blisters institutional pack ) . one strip contains fluticasone furoate ( 50 , 100 200 mcg per blister ) , strip contains vilanterol ( 25 mcg per blister ) . blister strip used create 1 dose . inhaler packaged within moisture-protective foil tray desiccant peelable lid following packs : ndc 0173-0916-10 breo ellipta 50/25 mcg 30 inhalations ( 60 blisters ) ndc 0173-0859-10 breo ellipta 100/25 mcg 30 inhalations ( 60 blisters ) ndc 0173-0859-14 breo ellipta 100/25 mcg 14 inhalations ( 28 blisters ) , institutional pack ndc 0173-0882-10 breo ellipta 200/25 mcg 30 inhalations ( 60 blisters ) ndc 0173-0882-14 breo ellipta 200/25 mcg 14 inhalations ( 28 blisters ) , institutional pack store room temperature 68\u00b0f 77\u00b0f ( 20\u00b0c 25\u00b0c ) ; excursions permitted 59\u00b0f 86\u00b0f ( 15\u00b0c 30\u00b0c ) [ usp controlled room temperature ] . store dry place away direct heat sunlight . keep reach children . breo ellipta stored inside unopened moisture-protective foil tray removed tray immediately initial . discard breo ellipta 6 weeks opening foil tray counter reads \u201c 0 \u201d ( blisters used ) , whichever comes first . inhaler reusable . attempt take inhaler apart .",
    "adverseReactions": "breo ellipta contraindicated following conditions : \u2022primary treatment status asthmaticus acute episodes chronic obstructive pulmonary disease asthma intensive measures required [ ( 5.2 ) ] . \u2022severe hypersensitivity milk proteins demonstrated hypersensitivity fluticasone furoate , vilanterol , excipients [ ( 5.11 ) , description ( 11 ) ] .",
    "ingredients": [
        {
            "name": "FLUTICASONE FUROATE",
            "code": "JS86977WNV",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_74899"
        },
        {
            "name": "VILANTEROL TRIFENATATE",
            "code": "40AHO2C6DG",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_75037"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        }
    ],
    "organization": "GlaxoSmithKline LLC",
    "name": "Breo Ellipta",
    "effectiveTime": "20241107",
    "indications_original": "BREO ELLIPTA is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for: \u2022 the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) \u2022 the maintenance treatment of asthma in patients aged 5 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 )",
    "contraindications_original": "\u2022 For oral inhalation only. ( 2.3 ) \u2022 Maintenance treatment of COPD: 1 actuation of BREO ELLIPTA 100/25 mcg once daily administered by oral inhalation. ( 2.1 ) \u2022 Maintenance treatment of asthma in adult patients aged 18 years and older: 1 actuation of BREO ELLIPTA 100/25 mcg or BREO ELLIPTA 200/25 mcg once daily administered by oral inhalation. ( 2.2 ) \u2022 Maintenance treatment of asthma in pediatric patients aged 12 to 17 years: 1 actuation of BREO ELLIPTA 100/25 mcg once daily administered by oral inhalation. ( 2.2 ) \u2022 Maintenance treatment of asthma in pediatric patients aged 5 to 11 years: 1 actuation of BREO ELLIPTA 50/25 mcg once daily administered by oral inhalation. ( 2.2 )",
    "warningsAndPrecautions_original": "BREO ELLIPTA is supplied as a disposable light grey and pale blue plastic inhaler containing 2 foil strips, each with 30 blisters (or 14 blisters for the institutional pack). One strip contains fluticasone furoate (50, 100 or 200\u00a0mcg per blister), and the other strip contains vilanterol (25\u00a0mcg per blister). A blister from each strip is used to create 1 dose. The inhaler is packaged within a moisture-protective foil tray with a desiccant and a peelable lid in the following packs:\n                  \n                     \n                        \u00a0NDC 0173-0916-10\u00a0\u00a0\u00a0\u00a0BREO ELLIPTA 50/25 mcg\u00a0\u00a0\u00a0\u00a030 inhalations (60 blisters)\n                     \n                        \u00a0NDC 0173-0859-10\u00a0\u00a0\u00a0\u00a0BREO ELLIPTA 100/25 mcg\u00a0\u00a0\u00a0\u00a030 inhalations (60 blisters)\n                     \n                        \u00a0NDC 0173-0859-14\u00a0\u00a0\u00a0\u00a0BREO ELLIPTA 100/25 mcg\u00a0\u00a0\u00a0\u00a014 inhalations (28 blisters), institutional pack\n                     \n                        \u00a0NDC 0173-0882-10\u00a0\u00a0\u00a0\u00a0BREO ELLIPTA 200/25 mcg\u00a0\u00a0\u00a0\u00a030 inhalations (60 blisters)\n                     \n                        \u00a0NDC 0173-0882-14\u00a0\u00a0\u00a0\u00a0BREO ELLIPTA 200/25 mcg\u00a0\u00a0\u00a0\u00a014 inhalations (28 blisters), institutional pack\n                  \n                  Store at room temperature between 68\u00b0F and 77\u00b0F (20\u00b0C and 25\u00b0C); excursions permitted from 59\u00b0F to 86\u00b0F (15\u00b0C to 30\u00b0C) [See USP Controlled Room Temperature]. Store in a dry place away from direct heat or sunlight. Keep out of reach of children.\n                  BREO ELLIPTA should be stored inside the unopened moisture-protective foil tray and only removed from the tray immediately before initial use. Discard BREO ELLIPTA 6\u00a0weeks after opening the foil tray or when the counter reads \u201c0\u201d (after all blisters have been used), whichever comes first. The inhaler is not reusable. Do not attempt to take the inhaler apart.",
    "adverseReactions_original": "BREO ELLIPTA is contraindicated in the following conditions:\n                  \n                     \n                        \u2022Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required [see Warnings and Precautions (5.2)].\n                     \n                        \u2022Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any of the excipients [see Warnings and Precautions (5.11), Description (11)].",
    "drug": [
        {
            "name": "Breo Ellipta",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_75043"
        }
    ]
}